It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In this second edition 22 new medications were added so NbN includes now 130 medications.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.

Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
We also added 4 additional dimensions
4 Additional Dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.

As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.

它已經很清楚，精神藥物的藥理目前的命名沒有反映我們當代的知識，也沒有正確地告知基於神經病學的處方的臨床醫生。很多時候，我們規定了“焦慮”症或“第二代抗精神病藥物”，以抑鬱症患者“抗抑鬱劑”。
這種做法是令人困惑的。
•五個國際組織ECNP，ACNP，AsCNP，CINP＆IUPHAR決定在五年前成立了一個工作組，並把它嵌入在命名我們目前的神經科學進步的使命。
•範圍是包括所有與CNS適應症的藥物，並利用這種新的命名，以幫助醫生時，他們正試圖找出什麼將是下一個合理的“neuropsychopharmacological一步”。
•在這第二版中新增了22個新的藥物等等的NbN現在包括130的藥物。
這個提議命名旨在反映當前的藥理知識基礎，並不能一定代表最終的科學道理。
該組裝的工作小組可能採取的立場，我們目前的知識基礎是不夠的，確定的主要目標和正確的行動機制。但作為一個工作小組，我們覺得這是更好地呈現尖端科學解釋，而不是等待明確的結論。我們現在需要把我們的病人，直到所有的事實都知道我們不能推遲治療。
 
因此，該命名是基於：
1.現在需要治療。
2.更新神經科學的見解。
3.工作隊成員的判斷。
沿著這些線路，我們已經提出了以下建議：
命名：
藥理學和行動模式 - 反映了有針對性的神經遞質/分子/系統進行修改和行動的模式/機制目前的認識和了解。
 我們還增加了4個額外的維度
4其他尺寸：
批准的適應症 - 基於主要監管機構的建議（如FDA，EMA等）
療效及副作用 - 從正的單，大，RCT和/或“重固體重量”臨床數據驅動。只有普遍的或危及生命的副作用被列入
實用注 - 總結了臨床知識已被“過濾”，通過專題組“篩子”
神經生物學 - 這方面的重點是生物學。它分為臨床前和臨床醫技科室，並把重點放在後者
對於那些想了解更多ABO從經驗data.ut藥理得出誰，有一個直接鏈接到IUPHAR的相關網站 - 我們在這方面的合作者。
 
由於這是正在進行的過程中，我們認識到，該產品是不完美的。 （並考慮到其他高校的反饋）根據大家的反饋新的報告和調查結果，（例如，以後的版本），將進行相應的更新。